Abstract：
OBJECTIVE: Aim: To evaluate the effectiveness of PSAE for secondary prevention of VB episodes in patients with chronic liver disease (CLD) and CSPH.
METHODS: Materials and Methods: One hundred twenty patients (from 2008 to 2020) were submitted of PSAE as secondary prevention treatment. The results of the treatment of 27 patients between 2008 and 2012 (first period) were compared with those of 93 patients treated with PSAE since 2013 (second period), as procedure and management protocol were modificated. VB recurrence rate and mortality (related and non-related to bleeding episodes) were defined as study end-points in both groups at 12-months follow-up.
RESULTS: Results: At 12-months follow-up, 11 (40,7 %) and 54 (58,1 %) patients in groups 1 and 2, respectively, were free from VBs (p=0,129). Overall mortality rate was significantly higher in group 1, as compared to group 2: 10 (37,0 %) versus 6 (6,4 %) patients, respectively (p<0,001), - due to higher frequency of fatal VB events (7 (26,0 %) vs. 3 (3,2 %) patients, respectively; p=0,001).
CONCLUSIONS: Conclusions: PSAE is an effective treatment for secondary prevention of VB in patients with CLD and CSPS. The management protocol modification resulted in the decrease in overall mortality rate and mortality related to recurrent VB episodes.
METHODS: Materials and Methods: One hundred twenty patients (from 2008 to 2020) were submitted of PSAE as secondary prevention treatment. The results of the treatment of 27 patients between 2008 and 2012 (first period) were compared with those of 93 patients treated with PSAE since 2013 (second period), as procedure and management protocol were modificated. VB recurrence rate and mortality (related and non-related to bleeding episodes) were defined as study end-points in both groups at 12-months follow-up.
RESULTS: Results: At 12-months follow-up, 11 (40,7 %) and 54 (58,1 %) patients in groups 1 and 2, respectively, were free from VBs (p=0,129). Overall mortality rate was significantly higher in group 1, as compared to group 2: 10 (37,0 %) versus 6 (6,4 %) patients, respectively (p<0,001), - due to higher frequency of fatal VB events (7 (26,0 %) vs. 3 (3,2 %) patients, respectively; p=0,001).
CONCLUSIONS: Conclusions: PSAE is an effective treatment for secondary prevention of VB in patients with CLD and CSPS. The management protocol modification resulted in the decrease in overall mortality rate and mortality related to recurrent VB episodes.
摘要：
目的：目的：评价慢性肝病（CLD）和CSPH患者二级预防VB发作的有效性。
方法：材料和方法：2008年至2020年，共提交了120例PSAE患者作为二级预防治疗。将2008年至2012年（第一期）的27例患者的治疗结果与自2013年（第二期）以来接受PSAE治疗的93例患者的治疗结果进行比较，作为程序和管理方案进行了修改。在12个月随访时，将VB复发率和死亡率（与出血发作相关和不相关）定义为两组的研究终点。
结果：结果：在12个月的随访中，第1组和第2组分别有11例(40,7%)和54例(58,1%)患者，没有VB(p=0,129)。与第2组相比，第1组的总死亡率明显更高：10（37,0％）对6（6,4％）患者，分别(p<0,001)，-由于致命的VB事件的频率较高（7（26,0％）与3（3，2％）患者，分别；p=0,001)。
结论：结论：PSAE是CLD和CSPS患者二级预防VB的有效治疗方法。管理方案的修改导致总死亡率和与复发性VB发作相关的死亡率降低。
方法：材料和方法：2008年至2020年，共提交了120例PSAE患者作为二级预防治疗。将2008年至2012年（第一期）的27例患者的治疗结果与自2013年（第二期）以来接受PSAE治疗的93例患者的治疗结果进行比较，作为程序和管理方案进行了修改。在12个月随访时，将VB复发率和死亡率（与出血发作相关和不相关）定义为两组的研究终点。
结果：结果：在12个月的随访中，第1组和第2组分别有11例(40,7%)和54例(58,1%)患者，没有VB(p=0,129)。与第2组相比，第1组的总死亡率明显更高：10（37,0％）对6（6,4％）患者，分别(p<0,001)，-由于致命的VB事件的频率较高（7（26,0％）与3（3，2％）患者，分别；p=0,001)。
结论：结论：PSAE是CLD和CSPS患者二级预防VB的有效治疗方法。管理方案的修改导致总死亡率和与复发性VB发作相关的死亡率降低。
